CC
EWTX icon

Checkpoint Capital’s Edgewise Therapeutics EWTX Stock Holding History

Checkpoint Capital’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-33,000
Closed -$361K – 19
2023
Q4 		$361K Buy
+33,000
New +$232K 0.22% 19

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Checkpoint Capital's EWTX Position: Q1 2024 in Review

Checkpoint Capital sold out of Edgewise Therapeutics (EWTX) in Q1 2024, closing a stake of 33,000 shares — an estimated $361K sold.

Checkpoint Capital first reported a position in EWTX in Q4 2023 and held it in 1 quarter. The position peaked at $361K in Q4 2023. 129 funds tracked by Wall St. Rank hold EWTX as of Q1 2024.

  • Checkpoint Capital reported no remaining Edgewise Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Checkpoint Capital sold 33,000 Edgewise Therapeutics shares in Q1 2024, an estimated $361K.
  • Checkpoint Capital first reported a position in Edgewise Therapeutics in Q4 2023 and held it in 1 quarter.
  • Checkpoint Capital's Edgewise Therapeutics position peaked at $361K in Q4 2023.
  • 129 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2024.

Based on Checkpoint Capital's 13F filing for Q1 2024, filed 15 May 2024.